Last reviewed 2026-06-10 · How we verify

Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet — Treatment Landscape & Competitive Intelligence

Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUF

Marketed treatment landscape

Approved drugs treating Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Pfizer Inc. · 1 drug in Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet:

• Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet treatment updates — RSS
• Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet treatment updates — Atom
• Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet treatment updates — JSON

Cite this brief

Drug Landscape (2026). Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-adult-patients-with-type-iv-hyperlipidemia-with-very-high-serum-triglyceride-elevations-2-000-mg-dl-presenting-risk-of-pancreatitis-unresponsive-to-diet. Accessed 2026-06-10.

Related

• Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing